Loader

Pathways

PathWhiz ID Pathway Meta Data

PW146319

Pw146319 View Pathway
drug action

Tocopherol Drug Metabolism Action Pathway

Homo sapiens

PW145874

Pw145874 View Pathway
drug action

Tofacitinib Drug Metabolism Action Pathway

Homo sapiens

PW176479

Pw176479 View Pathway
metabolic

Tofacitinib Predicted Metabolism Pathway

Homo sapiens
Metabolites of Tofacitinib are predicted with biotransformer.

PW127726

Pw127726 View Pathway
drug action

Tolazamide Action Pathway

Homo sapiens
Tolazamide is an hypoglycemic agent from the sulfonylurea class used in the treatment of non insulin dependent diabetes mellitus type II. Tolazamide lowers blood glucose by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. This drug binds to ATP-sensitive potassium-channel receptors on the pancreatic cell surface (known as the sulfonylurea receptor 1 (SUR1) subunit (Kir6.2)), reducing potassium conductance and causing depolarization of the membrane. This depolarization stimulates the calcium ion influx through voltage-sensitive calcium channels thus raising intracellular concentrations of calcium ions. The higher concentration of intracellular calcium ions induces the secretion (exocytosis) of insulin into the blood. Tolazamide is administered as an oral tablet.

PW144944

Pw144944 View Pathway
drug action

Tolazamide Drug Metabolism Action Pathway

Homo sapiens

PW176149

Pw176149 View Pathway
metabolic

Tolazamide Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Tolazamide are predicted with biotransformer.

PW132365

Pw132365 View Pathway
metabolic

Tolazoline Drug Metabolism

Homo sapiens
Tolazoline is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Tolazoline passes through the liver and is then excreted from the body mainly through the kidney.

PW144904

Pw144904 View Pathway
drug action

Tolazoline Drug Metabolism Action Pathway

Homo sapiens

PW127737

Pw127737 View Pathway
drug action

Tolbutamide Action Pathway

Homo sapiens
Tolbutamide is an oral antihyperglycemic agent from the sulfonylurea drug class. This drug is used to treat hyperglycemia in patients with type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus (NIDDM)). It is structurally similar to acetohexamide, chlorpropamide, and tolazamide. Sulfonylureas lower blood glucose in patients with NIDDM by directly stimulating the acute release of insulin from beta cells of pancreatic islet tissue. Sulfonylureas inhibit the ATP-potassium channels by linking with the subunit called the ATP-binding cassette sub-family C member 8 on the beta cell membrane and potassium efflux. This binding results in the depolarization of the cell. In consequence, it causes an influx of calcium ions thus releasing the insulin-containing granules by exocytosis. This drug is also an inhibitor of the ATP-sensitive inward rectifier potassium channel 1 presents in the kidney. Its pharmacological action is still unknown. Tolbutamide is administered as an oral tablet.

PW145213

Pw145213 View Pathway
drug action

Tolbutamide Drug Metabolism Action Pathway

Homo sapiens